Two pharma companies admit to illegal collusion over nortriptyline

Latest

Two pharma companies admit to illegal collusion over nortriptyline

In Latest

Two of the companies involved in a Government investigation into the supply of nortriptyline have confessed to illegally colluding with one another and with a third company in order to raise the prices the NHS paid for the drug.

The Competition and Markets Authority today (Friday September 20) revealed that King Pharmaceuticals and Alissa Healthcare Research had admitted sharing “strategic and competitively sensitive information” with one another and with Lexon UK between 2015 and 2017.

The CMA said that sharing the information, which concerned prices, volumes and entry plans, was aimed at artificially raising the prices the NHS had to pay for nortriptyline. NHS spending on the antidepressant peaked at £38m in 2015, the watchdog noted.

Lexon denies any wrongdoing, meaning the investigation is ongoing and the scale of any penalties has yet to be decided. If the CMA determines that Lexon was party to the infringement, its denial may mean it is not eligible for a "settlement discount" with regard to any financial penalties.

Lexon director Nitin Sodha stood down from the chairmanship and board of the National Pharmacy Association earlier this year after the CMA issued its provisional findings on a separate case involving prochlorperazine.

The CMA is also investigating whether King and Auden Mckenzie entered into an illegal agreement in 2014 whereby the former would supply only 25mg nortriptyline tablets and the latter 10mg tablets.

"A fine line"

A spokesperson for King Pharmaceuticals said that although it was "a small firm" [the Donegal-headquartered company has three drugs listed on the EMC] it was cooperating "fully" with the CMA and had "agreed a settlement" with the watchdog.

Alissa Healthcare also said it had "cooperated fully" with the CMA, adding: "While Alissa's motivation was to ensure that it was better-positioned to enter a new market to compete and drive benefits for customers (which it has a strong track record of doing) it accepts that its conduct, in this instance, strayed over a fine line.

"Alissa would also observe that during the period of the relevant infringement the price of the relevant product dropped significantly."

The company said it would seek to ensure legal compliance in the future "based on a more comprehensive understanding of competition law".

This article has been updated with comment from King Pharmaceuticals and Alissa Healthcare.

Record my learning outcomes

Latest

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Latest

People from deprived areas most likely to suffer diabetes complications

People living in socially deprived areas of Scotland are more likely to experience life-threatening complications of type 1 diabetes, according to a new study.

1 Min Article

bookmark_icon_off
Latest

MHRA warning over sweets contaminated with cannabis oil

A series of arrests have been made in West Yorkshire after sweets distributed in the area contained cannabis oil.

1 Min Article

bookmark_icon_off
Latest

Pharmacies forced to spend £5.5k on Covid measures

Pharmacies have spent £5,503 on average on Covid-19 related costs before medicines spend is accounted for, a new survey shows, with deliveries and staffing costs taking a particular toll on finances.

1 Min Article

bookmark_icon_off
Latest

Pharmacies could issue CDs without a prescription

Emergency measures would allow pharmacists to supply without a script, use SSPs and adjust instalments.

2 Min Article

bookmark_icon_off
Latest

Third of Covid-19 deaths linked to diabetes

Almost a third of all hospital deaths from coronavirus in England have been in people with diabetes, warns NHS England today in a new study.

1 Min Article

bookmark_icon_off
Latest

FIP: Pharmacists can fight WHO global health threats

The president of FIP said pharmacists can help address 10 threats to global health identified by the World Health Organization.

1 Min Article

Recommended Learning

bookmark_icon_off
Sponsored education

Advising on thrush treatment

This video looks at the distinctive benefits of different combination products and how to find the right treatment option for your customer.

7 Min Module

Sponsored education

7 steps to tackling children's allergy

Work through this new-style module to increase your confidence in reassuring parents of children with allergies, and know what advice and products to recommend

8 Min Module

bookmark_icon_off
Sponsored education

Challenge your thinking on warts and verrucas

Discover different treatment options for warts and verruas and when to recommend them to your customers, based on their individual needs

17 Min Module

Sponsored education

Dry eye consultations

Work through a customer consultation to determine the possible cause of stinging, gritty eyes and recommend an effective treatment to help ease these symptoms.

15 Min Module

Sponsored education

Treating fungal nail infections

Understand how fungal nail infections develop and help manage customer expectations around treatment

10 Min Module

bookmark_icon_off
Sponsored education

Pain conversations - making effective recommendations

Explore our detailed case studies to help understand how to advise customers on different causes of pain.

15 Min Module